SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Zacks News
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the fourth quarter of 2020.
Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod
by Zacks Equity Research
The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the third quarter of 2020.
SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.